XRCC3 Thr241Met Is Associated with Response to Platinum-Based Chemotherapy but Not Survival in Advanced Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Qiu, Mantang ^a,b   Xu, Lei ^a,b   Yang, Xin ^a,b   Ding, Xiangxiang ^a,b   Hu, Jingwen ^a,b   Jiang, Feng ^a   Xu, Lin ^a   Yin, Rong ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; THIONINE; THREONINE; XRCC3 PROTEIN;

ADVANCED CANCER; ALLELE; ARTICLE; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PREDICTIVE VALUE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; XRCC3 GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84885140904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077005     Document Type: Article

References (34)

1. Parkin DM, Pisani P, Ferlay J, (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841.
2. Bunn PA Jr, Kelly K, (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100.
3. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909.
4. Tahara E, Yasui W, Ito H, Harris CC, (2010) Recent progress in carcinogenesis, progression and therapy of lung cancer: the 19th Hiroshima Cancer Seminar: the 3rd Three Universities' Consortium International Symposium, November 2009. Jpn J Clin Oncol 40: 702-708.
5. Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, et al. (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27: 3217-3224.
6. Wu J, Liu J, Zhou Y, Ying J, Zou H, et al. (2012) Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res 18: 3972-3981.
7. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, et al. (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803.
8. Rodriguez J, Boni V, Hernandez A, Bitarte N, Zarate R, et al. (2011) Association of RRM1-37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. Eur J Cancer 47: 839-847.
9. Ryk C, Kumar R, Thirumaran RK, Hou SM, (2006) Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer 54: 285-292.
10. Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, et al. (2004) Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 25: 2433-2441.
11. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, et al. (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17: 668-675.
12. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, et al. (2012) Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol 14: 207-213.
13. Ke HG, Li J, Shen Y, You QS, Yan Y, et al. (2012) Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev 13: 4413-4416.
14. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, et al. (2012) Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 118: 2466-2475.
15. Butkiewicz D, Drosik A, Suwinski R, Krzesniak M, Rusin M, et al. (2012) Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer 131: E1100-1108.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
17. Ren SX, Zhou CC, Zhou SW, Zhang L, Su CX, et al. (2009) Predictive Role of ERCC1 and XRCC3 Gene Polymorphism on Response of Platinum-based Chemotherapy in Advanced NSCLC. Journal of Oncology 15: 706-710.
18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
19. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
20. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
21. Osawa K, Nakarai C, Uchino K, Yoshimura M, Tsubota N, et al. (2012) XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients. Int J Mol Sci 13: 16658-16667.
22. Provencio M, Camps C, Cobo M, De las Penas R, Massuti B, et al. (2012) Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol 70: 883-890.
23. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, et al. (2012) Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 7: 973-981.
24. Xu C, Wang X, Zhang Y, Li L, (2011) [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 14: 912-917.
25. Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, et al. (2011) Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol 6: 2018-2026.
26. Yin M, Liao Z, Huang YJ, Liu Z, Yuan X, et al. (2011) Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. PLoS One 6: e20055.
27. Ren S, Zhou S, Wu F, Zhang L, Li X, et al. (2012) Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. Lung Cancer 75: 102-109.
28. Zhou C, Ren S, Zhou S, Zhang L, Su C, et al. (2010) Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40: 954-960.
29. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, et al. (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22: 2594-2601.
30. Ford BN, Ruttan CC, Kyle VL, Brackley ME, Glickman BW, (2000) Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis 21: 1977-1981.
31. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, et al. (2000) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89: 160-166.
32. Bosken CH, Wei Q, Amos CI, Spitz MR, (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94: 1091-1099.
33. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, et al. (2001) XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22: 1437-1445.
34. Cohn LD, Becker BJ, (2003) How meta-analysis increases statistical power. Psychol Methods 8: 243-253.